Impact of COVID-19 pandemic on diagnosis and treatment access of patients with viral hepatitis in Turkey
Copyright (c) 2023 Fatma Eser, Rahmet Güner, Yunus Gürbüz, Meral Akdoğan, Zeynep Bilgiç, Nesibe Korkmaz, Derya Arı, Gamze Şanlıdağ, Şengül Kesim Uçar, Tolga Düzenli, Tansu Yamazhan..
INTRODUCTION: We aimed to evaluate access to diagnosis, treatment and follow-up in patients with viral hepatitis during the COVID-19 pandemic.
METHODOLOGY: Patients who started treatment for hepatitis B and hepatitis C were included in the study and analyzed in two periods: before-pandemic and during-pandemic. Indication for treatment and frequency of laboratory follow-up was obtained from hospital records. A telephone survey was administered to evaluate treatment access and compliance.
RESULTS: Four centers with 258 patients were included in the study. Of these 161 (62.4%) were male, median age was 50 years. The number of patients, admitted to outpatient clinics was 134647 in the before-pandemic period and 106548 in the during-pandemic period. Number of patients who started treatment for hepatitis B were significantly high during-pandemic period compared with before-pandemic (78 (0.07%); 73 (0.05%) respectively; p = 0.04). The number who received treatment for hepatitis C was similar in both periods: 43 (0.04%); 64 (0.05%), respectively (p = 0.25). Prophylactic treatment for hepatitis B, due to immunosuppressive agents was significantly higher in during-pandemic period (p = 0.001). In the laboratory follow-ups at 4th, 12th and 24th weeks of treatment, worse adherence was detected in during-pandemic (for all p < 0.05). Access to treatment and compliance of all patients was over 90% and did not differ in the two periods.
CONCLUSIONS: During-pandemic, hepatitis patients' access to diagnosis, treatment initiation and follow-up had worsened in Turkey. The health policy implemented during the pandemic had a positive impact on patients' access to and compliance to treatment.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:17 |
|---|---|
| Enthalten in: |
Journal of infection in developing countries - 17(2023), 4 vom: 30. Apr., Seite 461-467 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Eser, Fatma [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Access |
|---|
| Anmerkungen: |
Date Completed 11.05.2023 Date Revised 15.06.2023 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.3855/jidc.17585 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM356628868 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM356628868 | ||
| 003 | DE-627 | ||
| 005 | 20231226070851.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3855/jidc.17585 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1188.xml |
| 035 | |a (DE-627)NLM356628868 | ||
| 035 | |a (NLM)37159894 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Eser, Fatma |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Impact of COVID-19 pandemic on diagnosis and treatment access of patients with viral hepatitis in Turkey |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 11.05.2023 | ||
| 500 | |a Date Revised 15.06.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright (c) 2023 Fatma Eser, Rahmet Güner, Yunus Gürbüz, Meral Akdoğan, Zeynep Bilgiç, Nesibe Korkmaz, Derya Arı, Gamze Şanlıdağ, Şengül Kesim Uçar, Tolga Düzenli, Tansu Yamazhan. | ||
| 520 | |a INTRODUCTION: We aimed to evaluate access to diagnosis, treatment and follow-up in patients with viral hepatitis during the COVID-19 pandemic | ||
| 520 | |a METHODOLOGY: Patients who started treatment for hepatitis B and hepatitis C were included in the study and analyzed in two periods: before-pandemic and during-pandemic. Indication for treatment and frequency of laboratory follow-up was obtained from hospital records. A telephone survey was administered to evaluate treatment access and compliance | ||
| 520 | |a RESULTS: Four centers with 258 patients were included in the study. Of these 161 (62.4%) were male, median age was 50 years. The number of patients, admitted to outpatient clinics was 134647 in the before-pandemic period and 106548 in the during-pandemic period. Number of patients who started treatment for hepatitis B were significantly high during-pandemic period compared with before-pandemic (78 (0.07%); 73 (0.05%) respectively; p = 0.04). The number who received treatment for hepatitis C was similar in both periods: 43 (0.04%); 64 (0.05%), respectively (p = 0.25). Prophylactic treatment for hepatitis B, due to immunosuppressive agents was significantly higher in during-pandemic period (p = 0.001). In the laboratory follow-ups at 4th, 12th and 24th weeks of treatment, worse adherence was detected in during-pandemic (for all p < 0.05). Access to treatment and compliance of all patients was over 90% and did not differ in the two periods | ||
| 520 | |a CONCLUSIONS: During-pandemic, hepatitis patients' access to diagnosis, treatment initiation and follow-up had worsened in Turkey. The health policy implemented during the pandemic had a positive impact on patients' access to and compliance to treatment | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Hepatitis B | |
| 650 | 4 | |a Hepatitis C | |
| 650 | 4 | |a access | |
| 650 | 4 | |a treatment | |
| 700 | 1 | |a Güner, Rahmet |e verfasserin |4 aut | |
| 700 | 1 | |a Gürbüz, Yunus |e verfasserin |4 aut | |
| 700 | 1 | |a Akdoğan, Meral |e verfasserin |4 aut | |
| 700 | 1 | |a Bilgiç, Zeynep |e verfasserin |4 aut | |
| 700 | 1 | |a Korkmaz, Nesibe |e verfasserin |4 aut | |
| 700 | 1 | |a Arı, Derya |e verfasserin |4 aut | |
| 700 | 1 | |a Şanlıdağ, Gamze |e verfasserin |4 aut | |
| 700 | 1 | |a Kesim Uçar, Şengül |e verfasserin |4 aut | |
| 700 | 1 | |a Düzenli, Tolga |e verfasserin |4 aut | |
| 700 | 1 | |a Yamazhan, Tansu |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of infection in developing countries |d 2007 |g 17(2023), 4 vom: 30. Apr., Seite 461-467 |w (DE-627)NLM191178497 |x 1972-2680 |7 nnns |
| 773 | 1 | 8 | |g volume:17 |g year:2023 |g number:4 |g day:30 |g month:04 |g pages:461-467 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3855/jidc.17585 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 17 |j 2023 |e 4 |b 30 |c 04 |h 461-467 | ||